ZandCellZandCell
  • HOME
  • About
    • About
    • News Releases
  • Programs
  • Science
  • Apply
  • Contact
  • Login

    Lost your password?

  • 0
    Cart
  1. Home
  2. B. C. girl with leukemia seeks Christmas stem cell donor – DigitalJournal.com
  3. NEWS

NEWS

Oxford BioMedica could get $100 following CAR-T approval – pharmaphorum

Continue reading

2017-09-01 Michael Zand NEWS

New way to test antibiotics could lead to better drugs – Phys.Org

Oxford BioMedica could get $100 following CAR–T approval
pharmaphorum
UK biotech Oxford BioMedica could earn more than $100 million from Novartis for providing a key component in the recently approved CAR-T cancer cell therapy. The FDA this week approved Novartis’ chimeric antigen receptor T–cell (CAR-T) therapy …

and more »

Continue reading

2017-09-01 Michael Zand NEWS

CRISPR gives new insight into autoimmune disorders – Drug Target Review

Drug Target ReviewCRISPR gives new insight into autoimmune disordersDrug Target ReviewResearchers at The University of California Berkley(UCB) used a tool called CRISPR activation (CRISPRa), developed at The University of California, San Francisco (… Continue reading

2017-09-01 Michael Zand NEWS

Bio Roundup: CAR-T’s Huge Week, Merck’s ‘Pib Choice & More – Xconomy


Phys.Org

New way to test antibiotics could lead to better drugs
Phys.Org
For the new study, Collins wanted to apply synthetic biology—the construction of novel genetic circuits in living cells—to design bacteria that could be used to study antibiotics and infection. Most studies of how antibiotics work are done with …

and more »

Continue reading

2017-09-01 Michael Zand NEWS

Pioneering gene therapy approved for leukaemia in the US – New Scientist


Xconomy

Bio Roundup: CAR–T’s Huge Week, Merck’s ‘Pib Choice & More
Xconomy
The far-out idea of reprogramming a patient’s immune cells to fight cancer, known as CAR–T, entered the mainstream this week, and two numbers highlight the tale. The first is $11.9 billion, the price Gilead Sciences is paying for Kite Pharma and its …
Gilead’s Acquisition Of Kite Pharma Relieves Shareholders’ EnnuiSeeking Alpha

all 60 news articles »

Continue reading

2017-09-01 Michael Zand NEWS

Editas Medicine, Inc. (NASDAQ:EDIT) Stock Traded 16.1% Above Its 50 Day Average – First News 24

Editas Medicine, Inc. (NASDAQ:EDIT) Stock Traded 16.1% Above Its 50 Day AverageFirst News 24CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from Prevotella … Continue reading

2017-09-01 Michael Zand NEWS

Barclays Begins Coverage on Editas Medicine, Inc. (EDIT) With A Rating Of “Overweight” – Modern Readers


New Scientist

Pioneering gene therapy approved for leukaemia in the US
New Scientist
A CAR-T treatment – a type of gene therapy for cancer – has been approved for use in the US. Announced by the US Food and Drug Administration (FDA) on Wednesday, this is the first approval anywhere in the world for a type of CAR-T therapy, although the …
US clears breakthrough gene therapy for childhood leukemiaABC News
First Gene Therapy Treatment Approved in USSmithsonian
FDA approves a ‘historic’ new type of leukemia treatmentToday.com
FDA.gov –National Cancer Institute –National Cancer Institute –NPR
all 578 news articles »
Continue reading

2017-09-01 Michael Zand NEWS

Editas Medicine, Inc. (NASDAQ:EDIT) Stock Closed 16.1% Above Its 50 Day Average – Modern Readers

Editas Medicine, Inc. (NASDAQ:EDIT) Stock Closed 16.1% Above Its 50 Day AverageModern ReadersCRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from Prevotella… Continue reading

2017-09-01 Michael Zand NEWS
  • 1
  • …
  • 1,262
  • 1,263
  • 1,264
  • 1,265
  • 1,266
  • …
  • 3,595
Recent Posts
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Шведская компания ZandCell поставит 160 млн доз вакцины от COVID-19 в несколько стран мира 2021-07-22
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
About Us

ZandCell is a biotechnology company pioneering the advancements and therapeutic applications of Stem Cell Therapy. Our Technology is called “Regenerate”.

SiteLock
Contact Info
+1-702-425-9049
+46-736-779970
info@zandcell.com
Find us on map


Latest News
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Official PayPal Seal


© 2024 ZandCell. All Rights Reserved.
  • About
  • Programs
  • Science
  • Privacy Policy
  • Contact
  • RSS
  • Send us email
  • Follow us on Twitter
  • Follow us on Facebook
  • Follow Us on Linkedin
  • Call us via Skype
  • Follow Us on Instagram
  • Subscribe our YouTube Channel
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

Barclays Begins Coverage on Editas Medicine, Inc. (EDIT) With A Rating Of “Overweight”
Modern Readers
CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from Prevotella and Francisella 1), bound to a guide RNA molecule designed to recognize a particular …

and more »